INSUBCONTINENT EXCLUSIVE:
Biocon Biologics, in February, announced a settlement agreement in the United States for Bmab 1200
Photo: X@BioconBiologics2 min read Last Updated Aug 29 2024 | 11:54 AM IST
India's Biocon Biologics said on Thursday it has signed a
settlement and licence agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson - Johnson (collectively known as
Janssen).
The deal clears the way for commercialising Biocon's Bmab 1200, a proposed biosimilar that competes with Janssen's Stelara,
in Europe, the United Kingdom, Canada, and Japan
Biosimilar, according to one definition, is similar to another biological medicine that has already been approved, called the reference
arthritis.
Under the terms of a settlement agreement, Bengaluru-headquartered Biocon Biologics has resolved patent disputes with Janssen to
secure market entry dates in the markets listed above
proven track record of science and innovation and is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab)
Bmab 1200 will significantly strengthen our immunology franchise, enabling us to offer an affordable and effective treatment option for
Biologics, in February, announced a settlement agreement in the United States for Bmab 1200 and it is expected to launch the treatment in
February 2025 after getting approval from the US Food and Drug Administration.
Stelara (Ustekinumab) is a monoclonal antibody medication
that prevents the abnormal regulation of interleukin IL-12/23-associated immune diseases
The reference brand, Stelara, had worldwide sales of $10.85 billion in 2023.First Published: Aug 29 2024 | 11:54 AMIST
